3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Classical hematology
1
Conditions
Breast Neoplasms
17
Ovarian Neoplasms
11
Neoplasms
8
Fallopian Tube Neoplasms
8
Triple Negative Breast Neoplasms
7
Prostatic Neoplasms
6
Neoplasm Metastasis
6
Pancreatic Neoplasms
4
Endometrial Neoplasms
4
Neuroendocrine Tumors
3
Glioma
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Recurrence
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Fanconi Anemia, Complementation Group D1
2
Cholangiocarcinoma
2
Uveal Melanoma
1
Urogenital Neoplasms
1
Solid Tumors
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
SCLC,Extensive Stage
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
Platinum-sensitive Ovarian Cancer
1
Interventions
olaparib
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Fanconi Anemia, Complementation Group N
×
olaparib
×
Clear all
NCT04038502
2025-08-20
COBRA
VA Office of Research and Development
Phase 2
Recruiting
100 enrolled